Moderna Inc

Quantli Newsdesk

· 19 hours ago

On August 5, the FDA approved mFlusiva, Moderna's mRNA-based flu vaccine and the first of its kind cleared in the U.S. The approval marks a major milestone for Moderna as it expands its mRNA technology beyond COVID-19 vaccines into the seasonal flu market.

Quantli Newsdesk

· 22 days ago

Moderna appointed Michael McDonnell, a former CFO at Biogen and IQVIA, to its Board and Audit Committee as it navigates legal challenges over Covid-19 vaccine patents from CureVac. The governance move comes as the stock pulled back recently but remains up 93% year-to-date, reflecting investor focus on oversight and cost discipline during a transition period.

Quantli Newsdesk

· a month ago

Moderna appointed Michael McDonnell, former Biogen CFO with over 35 years of financial leadership experience, to its Board of Directors. The company is preparing for multiple product launches through 2027–2028, targeting cash breakeven by 2028, and awaiting an FDA decision on its flu vaccine in early August. Moderna also expects a $950 million settlement payment from patent litigation by July 8, 2026.

Quantli Newsdesk

· 2 months ago

Moderna presented its broadening mRNA pipeline at its annual Science Day, introducing mRNA-6007, an in vivo CAR-T therapy for autoimmune diseases set to enter clinical trials in 2026. The company also advanced T-cell engager programs in oncology and highlighted four approved products driving near-term growth.

Quantli Newsdesk

· 2 months ago

The FDA is reviewing Moderna's mFlusiva, an investigational mRNA-based flu vaccine, with a decision expected by August 5. If approved, it would mark the first mRNA flu vaccine and could be available for the 2026-2027 flu season, representing a major diversification beyond COVID-19 vaccines for the company.

Quantli Newsdesk

· 3 months ago

Moderna reported first-quarter revenue of $389 million, significantly exceeding Wall Street's estimate of about $224 million, driven by stronger-than-expected COVID-19 vaccine sales in international markets. The company posted a net loss that widened due to a $900 million litigation settlement charge related to vaccine technology patents. Despite the loss, Moderna reaffirmed its 2026 revenue growth target of up to 10%.

10-K

Quantli Newsdesk

· 4 months ago

Moderna reported total revenue of $1.9 billion for 2025, down 40% from $3.2 billion in 2024, driven primarily by declining COVID vaccine sales across all regions. Despite the revenue decline, net loss narrowed to $2.8 billion from $3.6 billion as the company reduced operating expenses by 30% through cost discipline and portfolio prioritization.